摘要
目的分析^131I治疗甲亢近期临床疗效。方法根据甲状腺质量和最高吸碘率等给予604例甲亢患者个性化^131I治疗,^131I于治疗后1、3、6、12个月随访,对甲亢、Graves眼病、甲亢性心脏病、低钾周期性麻痹、谷丙转氨酶升高、粒细胞减少及甲状腺大小等的转归进行回顾性分析。结果痊愈374例(61.9%),部分缓解101例(16.8%),甲减112例(18.5%),无效17(2.8%),总有效率为97.2%,治愈率为80.4%。^131I治疗Graves眼病总有效率83.7%,治疗甲亢性心脏病总有效率95.6%,同时可以缓解低钾周期性麻痹症状,改善肝功能,升高粒细胞,缩小甲状腺。结论^131I治疗甲亢及其伴发症安全有效,但要注意甲减等并发症的发生。
Objective To analyze the short - term clinical efficacy of ^131I therapy in hyperthyroidism. Methods 604 patients with hyperthyroidism were treated with individual ^131I therapy based on the quality and the highest thyroid iodine absorption rate, All patients were followed up for 1, 3,6 and 12 months after ^131I treatment, the outcome of Graves ophthalmopathy, hyperthyroidism heart disease, hypokalemic periodic paralysis, alanine aminotransferase increased, neutropenia and thyroid mass were analyzed retrospectively. Results Of the 604 patients, 61.9% (374/604) recovered, 16. 8% (101/604) were partial remission, 18.5% (112/604)were hypothyroidism, 2. 8% (17/604)were ineffective, total effective rate was 9% 2% , the cure rate was 80. 4%. ^131I treatment of graves eye disease had a total effective rate of 83.7% , total effective rate in treating hyperthyroidism heart was 95.6%, while periodic paralysis could relieve symptoms, improve liver function, elevated neutrophil and the decreased thyroid mass ( P 〈 0. 01 ). Conclusion ~31I therapy for hyperthyroidism is safe and effective, can be used as the preferred treatment, but the complications of hypothyroidism else must be considered.
出处
《浙江临床医学》
2010年第8期797-800,共4页
Zhejiang Clinical Medical Journal